Accu-Chek SmartGuide
Roche Diabetes Care
Roche's first CGM: a 14-day, factory-calibrated sensor (9.2% MARD) paired with a separate AI app that predicts lows 30 minutes out, forecasts glucose two hours ahead, and flags overnight hypo risk before sleep.
The scorecard
Overall MARD of 9.2% with 99.8% of readings in Parkes Error Grid zones A+B — solid single-digit accuracy, though a notch behind the 8.2% class leaders.[1]
Reads interstitial fluid like all current sensors, so the ~10-15 min physiological lag applies; the standout is a predictive app that forecasts ahead rather than reducing lag itself.[2]
Standalone monitor with its own two-app ecosystem (SmartGuide + SmartGuide Predict) plus mySugr; does not yet drive any commercial AID system or pump.[3]
Factory-calibrated, no fingersticks or scanning required; real-time readings every five minutes.[1]
Its defining feature: AI app predicts hypoglycemia within 30 minutes, forecasts glucose two hours ahead, and estimates nocturnal low risk at bedtime, on top of standard high/low alarms.[2]
All-in-one applicator and discreet on-body sensor; not the thinnest sensor but a clean, modern form factor.[1]
Available in 13+ countries and expanding toward 30+ across Europe, Latin America and Asia-Pacific; not US-marketed and reimbursement varies by country.[4]
The full picture
The Accu-Chek SmartGuide is Roche's first continuous glucose monitor — a 14-day, factory-calibrated sensor that streams a real-time reading every five minutes — but its real distinction is software, not hardware. Where most CGMs alert you once glucose is already high or low, SmartGuide pairs a standard monitoring app with a separate Predict app whose three machine-learning models look ahead: one flags a likely low within the next 30 minutes, one forecasts the glucose curve two hours out, and one estimates the risk of a nighttime low before you go to bed. Roche reports an overall accuracy of 9.2% MARD, with 99.8% of readings landing in the safe zones of the Parkes Error Grid. It is CE-marked for adults 18 and older with type 1 or type 2 diabetes on flexible insulin therapy, and a published study validated the predictive models on cohorts that included people with type 1 diabetes on both injections and pumps. The trade-offs are openness and reach: SmartGuide is a standalone tool that does not yet drive any automated insulin delivery system, it senses glucose only, and it is sold across Europe and a growing set of markets but not in the US.
Sources
- [1]Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes · manufacturer · 2024-07-09
- [2]Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App · peer-reviewed · 2024-08-19
- [3]Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration · manufacturer · 2025-09-01
- [4]Roche launches first AI-enabled continuous glucose monitor in the Middle East, offering two-hour and overnight predictive notifications · manufacturer · 2025-10-28